Markets Stocks Economy Crypto Earnings Banking Energy
Home› Stocks› Feature
Stocks · Exclusive

Sandoz price target raised but analysts keep Reduce rating

Sandoz price target raised but analysts keep Reduce rating
Stocks · 2026
Photo · Marcus Devlin for Daily Digest Invest
By Marcus Devlin Equities Correspondent Nov 17, 2026 4 min read

Shares of Sandoz, the Swiss generics and biosimilars maker, have been on a tear since they began trading in October 2023. Now one brokerage has nudged its price target higher — but it's not changing its cautious stance.

AlphaValue/Baader Europe lifted its target to 89.9 Swiss francs after Sandoz upgraded its 2026 guidance. The move reflects a slightly more optimistic view of the company's longer-term earnings power, particularly in biosimilars. But the firm kept its Reduce rating, arguing that after a roughly 260% run-up, the stock has already priced in a lot of the good news.

What's behind the target hike?

Price targets are typically built from an analyst's earnings forecast and the valuation multiple they expect the market to pay for those earnings. When a company raises its guidance, analysts often adjust their models — and that's what happened here.

AlphaValue/Baader said the guidance upgrade helps, but the bigger driver is biosimilars. These are lower-cost versions of complex biologic medicines, which are made from living cells and are far harder to copy than traditional chemical drugs. As patents on brand-name biologics expire, biosimilars can take significant market share, and they often carry better profit margins than conventional generics.

The brokerage expects the biosimilars market to grow quickly over the 2025-2035 period, which could lift Sandoz's profitability over time. It slightly raised its longer-term assumptions, including nudging its projected EBITDA growth rate — a measure of profit before interest, taxes, depreciation, and amortization — to 6% from 5.5%.

That may sound like a small tweak, but for a company with Sandoz's scale, even a half-percentage-point change in long-term growth can move the math on a price target.

Why keep a Reduce rating?

Despite the higher target, AlphaValue/Baader's Reduce rating signals that the analysts see limited upside from here. The stock has already surged about 260% since its listing, and that kind of rerating often means the market has already pushed the share price ahead of what the analyst's model suggests it's worth.

When a stock moves that sharply, the debate shifts from "is the business improving?" to "can expectations rise even further?" A higher price target doesn't always come with a higher rating because the share price may have moved faster than the analyst's spreadsheet.

In Sandoz's case, the brokerage is essentially saying: the company is doing well, but at this valuation, you're paying for a lot of future success. Unless results keep beating already-high expectations, there may not be much room for the stock to climb further.

What it means for investors

For everyday investors, this is a useful reminder that a price target hike isn't the same as a buy recommendation. Analysts can raise their target while still saying the stock is overvalued — the target just reflects where they think the shares should trade, not whether they think you should buy them.

Sandoz's story is a good one: it's a leader in biosimilars, a market with strong growth potential, and the company is executing well enough to upgrade its guidance. But after a 260% run, much of that good news may already be reflected in the share price.

For investors, the key question is whether Sandoz can keep delivering. The next earnings report and any further guidance updates will likely matter more than incremental sell-side upgrades. As we've seen with other stocks that have had big runs, the market's focus tends to shift from "is the business improving?" to "can it beat even higher expectations?"

That dynamic isn't unique to Sandoz. Other companies that beat and raise often see their stocks react less to the good news and more to whether the new targets are high enough. Similarly, analysts lifting targets on growth stories can still keep cautious ratings if the valuation has run ahead.

For now, Sandoz investors should watch for two things: whether the company can sustain its growth momentum, and whether the market is willing to pay an even richer price for that growth. The analysts at AlphaValue/Baader are saying the second part is the harder question.

More from this story

Next article · Don't miss

TSX slides to six-week low as AI jitters hit tech shares

Canada's main stock index dropped to its lowest close in nearly six weeks, dragged down by tech and industrial shares as investors grew nervous ahead of Nvidia's earnings. Materials edged higher after Panama agreed to reopen talks on First Quantum's Cobre Pana

Read the story →
TSX slides to six-week low as AI jitters hit tech shares